Table 2.

Targets in clinical trials in solid tumor CAR-T therapy.

Antigen	Tumors	ID
HER2	Central nervous system tumor, pediatric glioma	NCT03500991
Nectin4/FAP	Nectin4-positive advanced malignant solid tumor	NCT03932565
EGFR806	Central nervous system tumor, pediatric glioma	NCT03179012
Mesothelin	Ovarian, cervical, pancreatic, lung	NCT01583686
Lewis Y	Advanced cancer	NCT03851146
LMP1	Nasopharyngeal	NCT02980315
FR-α	Ovarian	NCT00019136
EGFRIII	Glioblastoma and brain tumor	NCT01454596
Glypican-3	Liver	NCT02932956
PSCA	Lung	NCT03198052
MUC1	Advanced solid tumors, lung	NCT03179007, NCT03525782
IL-13Rα2	Glioblastoma	NCT02208362
MAGE-A1/3/4	Lung	NCT03356808, NCT03535246
gp100	Melanoma	NCT03649529
Claudin 18.2	Advanced solid tumor	NCT03874897
EpCAM	Colon, pancreatic, prostate, gastric, liver	NCT03013712
PSMA	Prostate	NCT01140373
AXL	Renal	NCT03393936
CD171	Neuroblastoma	NCT02311621
CD20	Melanoma	NCT03893019
MUC16	Ovarian	NCT02311621
DR5	Hepatoma	NCT03638206
c-MET	Breast, hepatocellular	NCT03060356, NCT03638206
CD80/86	Lung	NCT03198052
DLL-3	Lung	NCT03392064